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Intestinal microbiota is constituted by a particular assembly of bacteria that develop symbiotic relationships with their host, contributing to diverse physiological functions and determining resilience to disease. Diverse environmental and intrinsic factors can upset this symbiotic relationship, shifting the ecosystem from a state of eubiosis to one of dysbiosis, which causes functional modifications and promotes disease. Indeed, immune dysfunction frequently coincides with intestinal dysbiosis and one can occur as a result of the other, creating a vicious circle. On this basis, hypotheses suggest that a dysbiotic gut microbiota could influence the onset and progression of celiac disease (CD). Epidemiological studies indicate that common perinatal and early postnatal factors influencing CD risk also affect the intestinal microbiota structure. A recent prospective study of healthy infants at family risk of developing CD has also revealed that the HLA-DQ genotype influences the microbiota composition. Several studies have also shown imbalances in the intestinal microbiota of CD patients, which are not fully normalized despite their adherence to a gluten-free diet, thus suggesting that such imbalances are not just a secondary consequence of CD. Furthermore, two small intervention studies have recently reported potential interest in the use of specific bifidobacteria to improve CD treatment, although larger human trials are required to confirm the benefits. Altogether, findings indicate that gut microbiota composition and function may be one of the missing pieces in the CD puzzle that could help to fully explain disease pathogenesis and risk. Thus, it is interesting to investigate new strategies for CD management that target gut microbiota within this research field.
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Introduction
Celiac disease (CD) is a chronic enteropathy triggered by cereal gluten proteins in genetically predisposed individuals. CD onset usually occurs in early childhood after the first exposure to dietary gluten; however, recent decades have witnessed an increase in the number of subjects experiencing gluten intolerance in their late adulthood 1 . This phenomenon is not fully explained by improvements in diagnosis and suggests changes in exposure to environmental factors that contribute to disease development.
The etiology of the disease is strongly associated with the genes of the human leukocyte antigen (HLA) that encode the HLA-DQ2 (HLA-DQ2.5 and HLA-DQ2.2) and HLA-DQ8 heterodimers expressed by antigen-presenting cells (APC). Gluten peptides bond to HLA heterodimers and are presented to T cells that trigger a complex immune response involving the innate and adaptive system. Most patients are carriers of the HLA-DQ2/DQ8 genes but this genotype is also present in about 40% of the general population and only a small percentage (2-5%) develops CD 2, 3 . This indicates that the HLA-DQ genotype is necessary but not solely responsible for development of the disease. Gluten is the main environmental trigger of CD but its intake neither fully explains the onset nor its clinical manifestations. In recent years, other environmental factors that influence the early gut microbiota composition such as type of delivery at birth and milk-feeding, intestinal infections and antibiotic intake, have also been associated with the risk of developing CD [2] [3] [4] [5] [6] [7] .
Observational studies of children and adult patients with CD (untreated and treated with a gluten-free diet (GFD)) revealed imbalances in their intestinal microbiota as compared to control subjects, which could contribute to the pathogenesis of the disease 8, 9 . This evidence suggests that the imbalances in gut microbiota are not only a secondary consequence of the inflammatory milieu characteristic of the active phase of CD but that they could also be a predisposing factor for disease development. However, the GFD per se also induced changes in gut microbiota composition of healthy adult subjects and could be partly responsible for the alterations detected in treated CD patients 10 . Therefore, to understand whether gut microbiota imbalances could play a role in CD onset, a prospective study is underway to investigate the early features of the intestinal microbiome in infants at family risk of CD development.
Currently, CD is among the most prevalent chronic digestive disorders but the only treatment is life-long adherence to a GFD. However, compliance with this dietary restriction is complicated due to the presence of gluten in most processed foods and patients are continuously exposed to gluten. Therefore, the identification of modifiable environmental factors that contribute to CD onset is critical for the development of strategies that lead to a reduction in disease incidence. This may be the case for components of the intestinal microbiota, whose acquisition could be modulated by environmental and dietary factors.
Here, we summarize the current understanding of the role played by intestinal microbiota in the etiopathogenesis of CD. We also discuss the possibilities of contributing to disease prevention and treatment by modulating gut microbiota composition and function.
Gut Microbiota Acquisition in Infants and CD Risk
The primary colonization of the intestinal microbiota begins at birth with the acquisition of microbes from the environment, mainly from the maternal vagina and the skin. It is a dynamic process that involves interactions of co-occurrence and exclusion between intestinal bacteria, reflecting life events of the newborn and undergoing changes until the first two-three years of age when the microbiome starts to converge toward a generic adult-like profile 11, 12 .
The intestinal colonization process leads to the acquisition and establishment of a protective microbiota that could modulate the risk of developing immune-mediated diseases in adulthood 13 . This influence is mediated by early gut microbiota and immune system interactions that are crucial for the development of tolerance towards harmless antigens from the diet and the microbiota.
Type of Delivery and Breast Feeding Practices
Perinatal and early postnatal environmental factors influencing the microbiota composition have been associated with CD susceptibility 14 . The greater risk of children born by caesarean section developing CD 15 might be attributed to the delay in intestinal colonization by bifidobacteria and the reduced bacterial diversity observed in caesarean-born compared to naturallydelivered infants 16 . Longer breast-feeding and particularly maintenance of breast-feeding when gluten is introduced seems to reduce the risk of developing CD or, at least, delays its onset in most case-control retrospective studies included in the meta-analysis by Akobeng et al. (2006) 17 . Also, feeding practices involving the gradual introduction of gluten simultaneous to breastfeeding were proposed as the protective agent responsible for reducing CD prevalence in one birth cohort compared to the "Swedish CD epidemic" cohort 18 . However, other prospective epidemiological and intervention studies failed to find a protective effect of breast-feeding in either CD autoimmunity or biopsy proven CD 19, 20 . These inconsistencies could be due to the implication of non-controlled variables (type of delivery, incidence of infections, amount of gluten in the diet, etc.) that confound the statistical analysis on breastfeeding effects. Duration of breast-feeding could be associated with a reduced or delayed exposure of the newborn to dietary gluten, which might contribute to the protective effect of breast milk. Plausibly bioactive breast milk components may also be involved in the potential protective effect of breast-feeding on CD development. For the infant's gut, breast milk is a source of bacteria 21, 22 and of human milk oligosaccharides (HMOs), which promote gut colonization by Bifidobacterium spp., possibly explaining the differences observed between the intestinal microbiota of breast-fed and formula-fed infants [23] [24] [25] . The beneficial properties of bifidobacteria on infants' health is widely accepted 26 , and scarcity of these bacteria have been associated with the onset of inflammatory bowel disease (IBD) 27 , type 1 diabetes (T1D) 28 and infant allergies 29 . Besides human milk provides many bioactive substances involved in passive immune protection and in immunological development of the neonate 30 . A complex network of chemo-attractants and cytokines in human milk are thought to play a role in compensating the developmental delay of the neonate immune system and in preventing the development of immune-mediated diseases 31 . Recent research has analyzed differences between breast-milk composition of healthy mothers and mothers with CD on a GFD 32 .
Mothers with CD presented a decrease in several immune markers (interleukin (IL)-12p70, transforming growth factor (TGF)-1 and secretory IgA (sIgA) and in numbers of Bifidobacterium spp. in breast-milk 32 . Likewise, these differences in the breast milk of CD mothers might influence the protective effects of breast-feeding on infant health, partly explaining the controversy across studies 32 . Similarly imbalances characterized by a lower content of immune mediators (interferon (IFN)-, TGF-2, IL-10 and sIgA) have been described and interpreted as a health risk factor for infants of allergic mothers 33, 34 . Furthermore, wheat gliadins and other gluten peptides have been detected in breast milk using specific IgA-antibodies against gliadin 35, 36 and the presence of gluten in breast milk has been suggested to play a role in the induction of oral tolerance of the breastfed infants. Thus, breast milk of mothers with CD following a GFD will lack this stimulus, and this might influence the future gluten tolerance of their offspring. However, as yet there is no evidence to support this hypothesis.
A number of epidemiological studies indicate that several perinatal factors participate in conjunction to modulate CD risk. However, there are no prospective studies revealing how differences in breast milk composition and in intestinal microbiota acquisition early in life might ultimately protect or contribute to CD onset.
Genotype and Intestinal Microbiota
Murine models using diverse mice strains congenic for major histocompatibility complex (MHC) genes indicate that MHC influences the composition of the faecal microbiota 37 . Recently a fish model using Gasterosteus aculeatus (threespine stickleback) has shown that the presence of certain MHC polymorphism is associated with altered abundance of some microbial families 38 . Over 30 years ago, Van de Merwe et al. 39 described that the faecal microbiota of monozygotic human twins was much more similar than that of dizygotic twins. Later a similar observation was reported for adults with varying degrees of relatedness 40 and identical twins, fraternal twins and unrelated controls 41 .The most recent study compared microbiota of 416 twin pairs and identified many microbial taxa whose abundances were influenced by host genetics. The family Christensenellaceae showed the highest heritability, which formed a co-occurrence network with other heritable bacteria and Archaea in lean individuals 42 . This evidence suggests that host genetics influence the composition of the human gut and that this influences the phenotype 42 . In the case of CD, a prospective study in a cohort of 164 infants with a family history of the disease reported associations between genetic risk (HLA-DQ genotype) and alterations in intestinal microbiota composition [43] [44] [45] .
The HLA-DQ2/8 genotype and the type of feeding (maternal or formula) influenced in conjunction the intestinal colonization analyzed by fluorescence in situ hybridization (FISH), real time PCR and denaturing gradient gel electrophoresis (DGGE) techniques [43] [44] [45] . In addition, specific decreases in Bifidobacterium spp. and B. longum and increases in Staphylococcus spp. were associated with higher genetic risk of developing CD irrespective of milk-feeding type 44 . The recent pyrosequencing analysis of the microbiota of a sub-cohort of 22 infants, all breast-fed and naturally delivered, confirmed that the HLA-DQ genotype influences per se the intestinal microbiota composition 46 . The high risk (HLA-DQ2 genotype) infant group showed an increase in the proportions of Firmicutes (Clostridium sensu stricto and unclassified Clostridiaceace and Gemella) and Protebacteria (Raoultella and unclassified Enterobacteriacea) and a reduction in Actinobacteria (Bifidobacterium). Associations have also been made between some Clostridium species, such as C. difficile, in ileal samples of human subjects and the NOD2 genotype and the phenotype of inflammatory bowel diseases 47 . A prospective study also reported that a reduction in the ratio of Bifidobacterium to Clostridium counts was associated with subsequent development of atopic dermatitis 48 . Another small study . This cohort of infants is being followed-up to monitor whether the intestinal microbiota alterations detected in early life are ultimately associated with CD onset. There is a strong association between CD and the expression of HLA-DQ2/DQ8 molecules compared to other HLA-linked diseases 52 , but several non-HLA genes also contribute to the disease 53 and their influence on the intestinal microbiota composition should not be discarded. For instance, non expression of the FUT2 gene coding for fucosyltransferase 2, leading to a non-secretor phenotype, has been associated with an increased susceptibility of developing CD 54 . Fucosyltranferase 2 is responsible for synthesising ABH antigens in the mucus and other secretions and its expression has also been associated with reduced diversity, richness and abundance of bifidobacteria in the human intestinal tract 55 . Therefore, both HLA-DQ2/8 molecules and the non-secretor phenotype due to FUT2 gene dysfunction have been linked with CD onset and also with reduced intestinal numbers of Bifidobacterium spp. This evidence, together with the reduced bifidobacteria levels detected in CD patients (described below; 9, 10), indicate this bacterial genus plays a role in CD risk.
Influence of Intestinal Microbiota in CD Pathogenesis
Several observational studies in children and adults with CD have shown alterations in the intestinal microbiota composition compared to control subjects. Our studies using molecular quantitative methods, such as FISH and quantitative PCR, found reduced numbers of Bifidobacterium spp. and B. longum and increased numbers of Bacteroides spp. in stools and duodenal biopsies of CD patients untreated and treated with a GFD compared to control subjects 8, 9 . Also enterobacteria and staphylococci numbers were higher in untreated CD patients than in controls, but these differences were almost restored in CD subjects on a long-term GFD 9 . Likewise, other studies in children reported increased prevalence of Bacteroides vulgatus and E. coli in CD biopsies before and after the GFD by temporal temperature gradient gel electrophoresis (TTGE) compared to controls 56 and lower numbers of Lactobacillus and Bifidobacterium and higher numbers of Bacteroides, Staphylococcus and enterobacteria in stools of children with CD compared to healthy controls 57 . Other studies performed by DGGE of the microbiota of adults with CD clustered the dominant microbial communities of healthy individuals together and separate from those of untreated CD patients 58 . However, the above study reported an increased prevalence in Bifidobacterium bifidum in patients with active CD as opposed to the lower bifidobacteria numbers detected in CD patients in our studies 9, 57, 59, 60 or the absence of differences reported in another study 61 . The analysis of metabolites derived from intestinal microbiota activity has also revealed significant differences between treated CD patients and healthy controls and suggests there is a metabolic signature for the CD microbiome 58, 59 . One of the most recent studies has also reported that CD patients with gastrointestinal symptoms had different microbiota composition when compared with controls and patients with dermatitis herpetiformis, suggesting that the microbiota may play a role in the manifestation of the disease 62 . In Sweden, an early study with samples collected between 1985-1996 revealed that rod-shaped bacteria were frequently associated with the mucosa of CD patients, both in the active phase and treated with a GFD, as detected by scanning electron microscopy (SEM) 63 . Later, these SEM analyses were complemented with 16S rDNA sequencing to identify the bacterial communities detected in the samples of the Swedish epidemic (1985) (1986) (1987) (1988) (1989) (1990) (1991) (1992) (1993) (1994) (1995) (1996) and in a new cohort of patients . We also carried out a deeper characterization of the CD microbiota by isolating bacterial strains and analyzing their pathogenic features [65] [66] [67] .
Specifically, E. coli clones belonging to virulent phylogenetic groups (B2 and D) isolated from untreated and treated CD patients presented a higher number of virulence genes encoding P fimbriae, capsule K5 and hemolysin than those isolated from healthy controls 65 . Furthermore, the abundance of the species Bacteroides fragilis coding for metalloproteases was increased in both untreated and treated CD patients, and thus could presumably play a pathogenic role in CD 66 . In fact, Bacteroides fragilis and the strains producing metalloproteases are frequently involved in opportunistic infections and aggravate colitis in animal models 68 . The isolation and identification of clones belonging to the genus Staphylococcus also revealed that the species S. epidermidis carrying the mecA gene (methicillin resistant gene) was more abundant in the CD patients (treated and untreated) than in controls 67 .
Potential Mechanism of Action of Intestinal Microbiota in CD
The microbiota and its alteration could contribute to the etiopathogenesis of CD by providing proteolytic activities that influence the generation of toxic and immunogenic peptides from gluten 66, 69 ; and by mediating-host-microbe interactions, which could influence the intestinal barrier Similarly, Fernandez-Feo et al. 74 and Caminero et al. 75 isolated species from the oral cavity and faeces able to hydrolyse gluten peptides; however, their physiological effects have not been evaluated. 72 .The microbiota could contribute to the etiopathogenesis of CD by (2) providing proteolytic activities that influence the generation of toxic and immunogenic peptides from gluten 66, 69 and by mediating host-microbe interactions which could influence (1) the intestinal barrier 70 and (3) We could hypothesize that this increased TLR expression in biopsies of CD patients may intensify gut microbiota signalling and host response to intestinal dysbiosis although direct evidence is not available.
Figure 1. Schematic representation of CD pathogenesis and the potential role of intestinal dysbiosis. Some gluten peptides cross the intestinal epithelium and can be deamidated by the tissue transglutaminase (tTG), which increases their ability to bind the HLA-DQ2/8 molecules of antigen-presenting cells and to trigger an adaptive immune response, involving Th1, Th2 and Th17 cells that lead to the release of proinflammatory cytokines (IFN-, interleukin (IL)-21, etc.) and the production of CD antibodies; other gluten peptides activate the innate immune response by interacting with eptithelial cells and APCs and, thus, trigerring the activation of inflammatory pathways (NF B) and the production of inflammatory cytokines such as IL-15. In κ particular, IL-15 increases the expression of the MICA molecule at epithelial cell surface and triggers activation of intraepithelial lymphocytes through engagement of NKG2D, leading to an innate-like cytotoxicity toward epithelial cells and enhanced CD8 T cell-mediated adaptive response, contributing to villous atrophy

Gluten Intake and Intestinal Microbiota
The only treatment for CD is adherence to a life-long GFD, which implies important dietary changes. Specifically, women on a GFD have a reduced dietary protein and fibre intake and an increased fat intake 82 . These dietary differences also seem to cause changes in the intestinal microbiota composition and in the immune response to the altered microbiota in vitro.
After three months of adherence to the GFD, children with CD showed increases in the B. fragilis group and Enterobacteriaceae numbers and in sIgA levels in stools 83 . In healthy adults the GFD caused shifts in gut microbiota composition, characterized by reduced numbers of Bifidobacterium spp., B. longum and the Lactobacillus group, and increased numbers of Enterobacteriaceae and E. coli 10 . This led to the proposal that GFD should be considered as an environmental factor that may contribute to shaping the microbiota composition in treated CD patients 10 .
In animal models, gut microbiota changes have also been related to the GFD but the data are not comparable to humans. For example, GFD-induced changes in the microbiota of NOD mice are characterized by higher numbers ; however, direct evidence is lacking.
Role of Probiotics in CD: Human Studies
There are proposals to use of some probiotic bacteria in CD management Both studies suggest the potential interest of these probiotic bacterial strains for improving CD treatment, although larger human trials are required to confirm and strength of this evidence.
Conclusions
Most studies demonstrate associations between CD and shifts in the composition of intestinal microbiota. These alterations are not only consequence of the inflammatory status characteristic of the active phase of the disease because the ecological perturbations are not completely restored after adherence to a GFD, even though the GFD per se also influences the microbiota composition. In healthy infants at family risk of CD, prospective studies also indicate that alterations in gut microbiota composition are associated with the HLA-DQ genotype and could influence CD onset. The influence of gut microbiota composition on the etiopathogenesis of CD could be related to its proteolytic activity and ability to generate toxigenic and immunogenic peptides and, particularly, to its ability to regulate gut barrier function and the immune response to gluten. Further and larger studies are, however, necessary to confirm that gut microbiota modulation by the administration of specific bacterial strains could contribute to improving the health status of CD subjects, and to reducing the risk of CD development.
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